Zheng Xinyu, Zhang Yingyue, Wang Yun, He Zijing, Zhang Qiang, Ren Dapeng, Yan Xiao, Yuan Xiao
Department of Orthodontics, The Affiliated Hospital of Qingdao University, Qingdao, China.
School of Stomatology of Qingdao University, Qingdao, China.
Front Surg. 2023 Mar 3;10:1052100. doi: 10.3389/fsurg.2023.1052100. eCollection 2023.
Hepatocellular carcinoma (HCC) is a common cause of cancer-related death in humans. Increasing evidence indicates that an imbalance in N6-methyladenosine (m6A) methylation is linked to the occurrence and development of cancer. We then developed a prognostic model as an independent risk factor with which predict the prognosis of HCC.
We obtained the gene expression and clinical data of HCC patients from the TCGA databases. The prognostic value of m6A methylation-related genes in patients who had HCC were subjected to comprehensive bioinformatics analysis. We use to construct the risk scoring formula. We collected pathological specimens from 68 patients who had HCC, and conducted immunohistochemical staining experiments on the specimens.
There was a significant correlation between candidate m6A methylation-related genes (YTHDF2, METTL14 and ZC3H13) overall survival of HCC patients. Among the 68 HCC patient specimens that underwent immunohistochemical staining, all cancer tissues were positive for METTL14, YTHDF2, and ZC3H13 staining in contrast to the adjacent tissues. We conducted a Kaplan-Meier survival analysis. The results showed that patients who had low METTL14 expression had a longer survival time than those of patients who had high METTL14 expression. Also, patients with low YTHDF2 expression had a longer survival time than patients with high YTHDF2 expression. Finally, patients with high ZC3H13 expression lived longer than those with low ZC3H13 expression. This result is consistent with the bioinformatics analysis conclusion above.
Generally, the prognostic model that was based on m6A methylation-related genes in this study can effectively predict the prognosis of HCC patients.
肝细胞癌（HCC）是人类癌症相关死亡的常见原因。越来越多的证据表明，N6-甲基腺苷（m6A）甲基化失衡与癌症的发生和发展有关。然后，我们开发了一种预后模型作为独立危险因素，用于预测HCC的预后。
我们从TCGA数据库中获取了HCC患者的基因表达和临床数据。对HCC患者中m6A甲基化相关基因的预后价值进行了全面的生物信息学分析。我们使用……构建风险评分公式。我们收集了68例HCC患者的病理标本，并对标本进行了免疫组织化学染色实验。
候选m6A甲基化相关基因（YTHDF2、METTL14和ZC3H13）与HCC患者的总生存期之间存在显著相关性。在接受免疫组织化学染色的68例HCC患者标本中，与相邻组织相比，所有癌组织中METTL14、YTHDF2和ZC3H13染色均为阳性。我们进行了Kaplan-Meier生存分析。结果显示，METTL14表达低的患者比METTL14表达高的患者生存期更长。此外，YTHDF2表达低的患者比YTHDF2表达高的患者生存期更长。最后，ZC3H13表达高的患者比ZC3H13表达低的患者寿命更长。这一结果与上述生物信息学分析结论一致。
总体而言，本研究基于m6A甲基化相关基因的预后模型能够有效预测HCC患者的预后。
